Clinical Trial Search

Primary: Acceptability of Enrollment and Randomization: Eligible But Declined Participation — 0; 0 Participants

Primary: The Percentage of Patients Attending a Primary Care Visit in Each of 3 Four-month Periods (First Measure) — 55.8; 55.6; 45.7 percent in care each 4 month period

Primary: Linkage to Care - Participants Who Received Cluster of Differentiation 4 (CD4) T-cell Count Test Result Within 3 Months of Testing HIV-positive (Binary) — 80; 121; 119…

Primary: Enrollment in Evidence-Based Parenting Program — 27; 12 Participants — p=0.006

Primary: Retention in Care - Yes Responses — 19; 23 Participants

Primary: Number of Participants Enrolled in Each Recruitment Arm — 182 Participants

Primary: Loneliness — 48.76; 44.44 units on a scale

Primary: Change in Decisional Conflict Scale — 0.55 score on a scale — p=.95

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type I Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/mL at Week 12 — 24.4; 20.9…

Primary: Number of Eligible Participants Who Are Successfully Recruited and Attend at Least One Group Session — 20 Participants

Primary: Number of Particpatns Who Considered the Intervention Feasible and Acceptable — 20 participants

Primary: Change in the Addiction Treatment Accessibility and Utilization as Assessed by Change in Likert Scale — 1.26; 1.07; 1.12; 1.03 score on a scale — p=0.84

Primary: Enrollment in Medication Assisted Treatment at 1-month Post-enrollment — 33; 1 participants

Primary: Number of Participants Attending at Least One Outpatient Visit — 85; 70 Participants

Primary: Percent of Participants Reporting Changes in Their HIV Testing Behavior Using Self-report Questionnaires — 185; 171; 2 Participants

Primary: Number of Participants With Hazardous Alcohol Use at Baseline, 3 and 6 Month Follow up — 41; 26; 18; 27 Participants — p=.002

Primary: Staff Surveys--Youth Engagement (YE) Prevention Programming Value — 4 score on a scale

Primary: Center for Epidemiological Studies-Depression Scale — 36.84; 40.90 units on a scale

Primary: Buprenorphine Treatment Adherence — 19.7; 16.1 percentage of urine samples — p=0.914

Primary: Changes in HIV Medication Adherence Throughout Intervention Phase — 60.0; 28.2 percentage of days adherent to Wisepill — p=.01

Primary: Number of Participants With Positive Urine Drug Screens at 5 Months Post-baseline — 18; 13 participants

Primary: Identify and Utilization of Primary Care Provider (PCP) — 426; 114; 771 Participants — p=0.624

Primary: Number of Participants Completing HCV Treatment — 3; 6 Participants

Primary: Change in Patient Activation, as Measured by Patient Activation Measure - 13 — 2.94; 1.78 units on a scale — p=0.048

Primary: Proportion of Participants With HIV Viral Load ≥832 Copies/mL (HemaSpot DBS) — 5; 7; 8; 4 Participants — p=.33

Primary: Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled…

Primary: Number of Women Retained in Care — 160; 164 Participants

Primary: Engagement in Biosensor Wearing — 20.6; 25.0 percentage of time worn — p=0.698

Primary: Demonstrated Drug Risk Reduction Skills (0-100%) — 40.60; 42.75 Percentage of correct steps

Primary: Acceptance of Health Message — 5.5; 5.4 units on a scale — p=0.18